Novavax (NVAX) 10-K2009 FY Annual report

Filed: 16 Mar 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: aggressively, air, alliance, Appendix, ASC, ASU, ATM, attestation, authoritative, Avimex, awaiting, BARDA, Baxter, BioCryst, Biomedical, bioreactor, borne, budget, campaign, CDC, Cervarix, cheaper, Codification, cohort, combat, cooperate, corona, Corrupt, cotton, County, CPLB, cytotoxic, de, decline, deliverable, demolition, description, difficulty, diminished, disaggregation, distinct, DMID, dozen, Dr, Driscoll, earliest, eleven, Engerix, Equiserve, Erck, Estasorb, expedited, export, expropriation, extinguished, Forbearance, franchise, Frederick, gene, Genzyme, GIV, GP, ground, HB, Henry, HHS, ID, IGEN, indirectly, inflation, Intercell, Iomai, Kelly, kill, Laboratorio, larger, learning, Liberty, licensure, magnitude, MaxCyte, McNicoll, MdBio, mechanical, media, Microbiology, military, Mitch, Mitchell, MLV, modestly, Modi, Montgomery, multiplied, notification, nucleic, OXIGENE, papilloma, passed, permanent, placebo, political, proceed, Procept, pronouncement, proof, proportionate, purified, rabbit, Rajiv, Recombivax, recommended, regional, residual, RFP, Rock, ROVI, Schein, seed, Specimen, Stanley, stimulate, stir, strictly, strive, subtenant, Subtopic, swine, tank, trend, Trizzino, unadjusted, unattractive, underwritten, unforeseen, vendor, Vlak, Xcellerex, York

Removed: accompanied, accounted, Alabama, APB, appeal, ARB, assured, bad, begun, billing, Birmingham, build, Bulletin, buyer, Canada, carryforward, Chapter, clarified, comprehensively, concurrent, consecutive, consortium, consuming, conversion, convert, creation, DCED, DEA, death, deducting, Department, designated, diluted, disadvantage, disorder, divestiture, dividing, efficient, elicited, emergence, Emory, encouraging, end, enterprise, envelope, environment, escalation, Esprit, exclusively, expiration, explore, externally, female, fin, firmly, flexibility, fluctuation, footnote, framework, generation, Genome, geographic, group, Gynodiol, half, Harvard, HGS, hypoactive, IA, implementation, inflammatory, innovative, internally, invest, involving, joined, journal, leading, line, linked, machinery, mature, measuring, mentioned, micellar, monath, month, morbidity, mortality, mutually, nano, noncompetitive, nonexclusive, North, noted, oil, onForm, optimize, optional, origin, overhead, partial, participated, participation, pathogenic, people, perspective, persuasive, Pharma, Philadelphia, placement, planning, pneumonia, poultry, preceding, preclinical, Prepaid, prevailing, preventive, priced, pro, problem, progression, prospective, quantity, reassortment, reciprocal, reclassified, redeem, redemption, reimbursing, remote, renewal, repositioned, resignation, restructuring, retained, run, SAB, satisfactory, seller, sensitivity, separation, sexual, shelf, skin, specialty, sponsor, staggering, supportive, tananbaum, testosterone, therapeutic, thereon, tolerization, toll, topical, transitioned, transport, uncertainty, unqualified, unregistered, unused, urgent, viewed, vulnerability, widespread, young

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

NVAX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have issued our report dated March 16, 2010, with respect to the consolidated financial statements, schedule and internal control over financial reporting included in the Annual Report of Novavax, Inc. and subsidiary on Form 10-K for the year ended December 31, 2009. We hereby consent to the incorporation by reference of said report in the Registration Statements of Novavax, Inc. and subsidiary on Forms S-3 (No. 333-118210 effective August 13, 2004; No. 333-118181 effective August 12, 2004; and No. 333-22685 effective March 4, 1997) and on Forms S-8 (No. 333-145298 effective August 9, 2007; No. 33-80277 effective December 11, 1995; No. 33-80279 effective December 11, 1995; No. 333-130990 effective January 12, 2006; No. 333-110401 effective November 12, 2003; No. 333-97931 effective August 9, 2002; No. 333-46000 effective September 18, 2000 and No. 333-77611, effective May 3, 1999).

/s/ Grant Thornton LLP

Baltimore, Maryland

March 16, 2010